Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

This study is testing whether adding a checkpoint inhibitor drug called SHR-1701 to standard chemotherapy and radiation before surgery can improve outcomes for patients with locally advanced rectal cancer — meaning cancer in the rectum that has grown significantly but has not yet spread to distant organs. **You may be eligible if...** - You are between 18 and 75 years old - You have been newly diagnosed with rectal cancer confirmed by pathology - Your cancer meets criteria for being locally advanced (e.g., growing into surrounding tissue or lymph nodes) - You have not received any prior cancer treatment (no surgery, chemo, radiation, or immunotherapy) - You are in good overall health (ECOG score 0–1) - You are able to swallow pills - You plan to have surgery after the treatment course **You may NOT be eligible if...** - You are allergic to the study drugs or similar agents - You have previously received cancer treatment for this diagnosis - You have serious autoimmune, liver, or other major organ conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.